Swayampakula Ramakanth, an analyst from H.C. Wainwright, has initiated a new Buy rating on Actuate Therapeutics, Inc. (ACTU).
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight the potential of Actuate Therapeutics, Inc. in the treatment of metastatic pancreatic cancer (mPC). The company is advancing its novel drug, elraglusib, which has shown promising interim Phase 2 results. These results indicate that the drug, when used in combination with standard chemotherapy, significantly improves overall survival rates and is well tolerated by patients, reducing the risk of death by 37% compared to chemotherapy alone.
Furthermore, the market for first-line mPC treatment in the U.S. is substantial, exceeding $3 billion, with a significant unmet need due to the limited efficacy of existing chemotherapy regimens. Elraglusib’s ability to target GSK-3β, a kinase involved in oncogenic processes, and its multi-pronged mechanism of action, including overcoming chemoresistance, make it a strong contender in this market. With a current valuation of $141 million and a projected revenue potential of nearly $600 million by 2033, Actuate Therapeutics is considered undervalued, presenting an attractive opportunity for long-term investors.